Elutia Inc (ELUT) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Elutia Inc   (NASDAQ: ELUT)


Elutia Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Elutia Inc 's ROA in the second quarter of 2026?
Elutia Inc achieved a return on average assets (ROA) of 108.72 % in its second quarter of 2026, this is above ELUT's average return on assets of -43.96%.
Elutia Inc assets over the 12 months ending in its second quarter of 2026 are valued at $48 million

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 7 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 35, from total ROA ranking in the first quarter of 2026 at 41.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 28.95 % 40.49 % 72.59 % -39.25 % -19.22 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 52 50 53 -26 -21
Return On Assets (TTM) 108.72 % 110.27 % 129.48 % -75.72 % -54.08 %
ELUT's Total Ranking # 35 # 41 # 4241 # 4153 # 4501
Total Assets (TTM) in million 44 55 62 29 34
Seq. Total Assets Change -20.94 % -11.45 % 112.02 % -13.12 % -13.87 %
Seq. Net Income Change - - - - -

ELUT's 5 Years Annual ROA >> Back to ELUT Management Effectiveness >> Compare ELUT ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 2
Sector # 8
Overall # 33

Return On Assets Statistics
High Average Low
129.48 %
-43.96 %
-148.88 %
(Dec 31 2025)   (Jun 30 2024)



  News about Elutia Inc Return on Assets ROA

Elutia Inc. Underscores Resilience Amid Global Tariff Challenges and Highlights Efficacy of EluPro BioEnvelope in Preventing Cardiac Device Infections

In a significant update from Silver Spring, Maryland, Elutia Inc. (Nasdaq: ELUT), a prominent innovator in the realm of drug-eluting biomatrix products, has confirmed that the ongoing global tariff environment has not materially impacted its commercial or operational performance. This announcement comes at a critical juncture for the company, particularly as it faces market fluctuations and economic uncertainties that have altered the landscape for many industries.Earlier in September 2024, Elutia also made waves in the medical device sector with the recent unveiling of a pivotal publication that validates the efficacy of its flagship product, the EluPro Antibiotic-Eluting BioEnvelope. A groundbreaking peer-reviewed study has highlighted the EluPro s remarkable ability to combat infections commonly associated with the implantation of cardiac devices. This research, conducted through an established preclinical infection model, presents robust evidence of the product s efficacy, suggesting that it can significantly reduce the incidence of post-implantation complications in cardiac procedures.



Financial Statements
Elutia Inc 's Assets $ 44 million ELUT's Balance sheet
Elutia Inc 's Income $ -8 million Quarterly ELUT's Income Statement
ELUT's Income by Division See ELUT's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 72.59 % -16.81 % -36.92 % 2.49 % -18.89 %
Total Assets in million 62 36 43 69 67
Y / Y Net Income Change - - - - -
Net Income in million 53 -54 -38 -33 -25
Annual Return On Assets 85.61 % -149.33 % -86.71 % -47.79 % -36.97 %

ELUT's 5 Years Annual ROA >> Back to ELUT Management Effectiveness >> Compare ELUT ROA to its Competitors



Comment on ELUT's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 85.61 % compared to prior year, due to annual net income growth of % to $53.38 million, while value of Elutia Inc 's overall assets grew just by 72.59 % to $62.35 million, compared to $62.35 a year before.


More Return On Assets Ratios
ELUT's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ELUT's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ELUT's Competitors
Subscribers only: Roa for Elutia Inc 's Suppliers
Subscribers only: Return On Assets for ELUT's Customers

You may also want to know
ELUT's Roi ELUT's Inventory Turnover Ratio ELUT's Growth Rates ELUT's Dividend Comparisons
ELUT's Profitability Ratios ELUT's Asset Turnover Ratio ELUT's Dividend Growth
ELUT's Roe ELUT's Valuation Ratios ELUT's Financial Strength Ratios ELUT's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Glucotrack Inc   151.40 %
Capforce Inc   141.40 %
Protagenic Therapeutics Inc new  137.58 %
Elutia Inc   108.72 %
Silexion Therapeutics Corp  99.09 %
Quince Therapeutics Inc   88.46 %
Interpace Biosciences Inc   85.91 %
Rigel Pharmaceuticals Inc  72.27 %
Traws Pharma inc   71.80 %
Actinium Pharmaceuticals Inc  71.73 %
Oramed Pharmaceuticals Inc  64.18 %
Atlantic Coastal Acquisition Corp Ii  54.09 %
Agenus Inc  44.86 %
Earth Science Tech Inc   44.02 %
Idexx Laboratories Inc  33.61 %
Mettler toledo International Inc   24.86 %
Medpace Holdings Inc   24.84 %

Date modified: 2026-08-17T17:18:24+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.